Caelum Diagnostic Solutions develops the RPIDx device for rapid, AI-driven cancer diagnosis at the point of biopsy. This system provides functional pathology results in five minutes by distinguishing between cancer and benign cells using FLIM-based metabolic activity. The automated platform enables immediate diagnostic feedback for accelerated cancer care without requiring an on-site pathologist.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer diagnostic methods rely on histopathology analysis of tissue biopsies, a process that is labor-intensive and can take several days to produce results. This delay between biopsy and diagnosis can lead to delayed treatment, increased patient anxiety, and the need for repeat biopsies. The extended turnaround time also impacts hospital efficiency and costs.
Solution
Caelum Diagnostic Solutions offers the RPIDx™, an AI-assisted diagnostic device that provides real-time cancer diagnosis during the initial biopsy procedure. The device utilizes Fluorescence Lifetime Imaging (FLIM) to detect metabolic activity indicative of cancer, delivering biopsy results in approximately 5 minutes. The RPIDx™ automates the diagnostic process, eliminating the need for manual analysis and reducing the potential for human error. By providing rapid, point-of-care results, the RPIDx™ aims to accelerate cancer care, improve patient outcomes, and enhance the efficiency of medical centers.
Target Audience
The primary target audience includes cancer centers, community-based hospitals, ambulatory surgical centers, interventional radiology clinics, and dermatology and medical offices.
Features
- AI-based diagnostic device providing biopsy results in approximately 5 minutes
- Utilizes Fluorescence Lifetime Imaging (FLIM) for metabolic activity detection
- Fully automated diagnosis, eliminating the need for human analysis
- Point-of-care rapid diagnosis adjacent to patient bedside
- Requires no additional training for hospital staff